Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 1 54-1, 2003, Pages

  Chabrashvili, Tina ^a   Kitiyakara, Chagriya ^a   Blau, Jonathan ^a   Karber, Alex ^a   Aslam, Shakil ^a   Welch, William J ^a   Wilcox, Christopher S ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Angiotensin receptor blocker; Candesartan; Isoprostane; Malonyldialdehyde; PD 123,319

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; CANDESARTAN HEXETIL; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN; PROTEIN NOX 1; PROTEIN NOX 4; PROTEIN P22PHOX; PROTEIN P67PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; INFUSION; KIDNEY CORTEX; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0037974569     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00476.2002     Document Type: Article

References (51)

1. Babior BM. NADPH oxidase: an update. Blood 93: 1464-1476, 1999.
2. Barton CH, Ni Z, and Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 60: 1083-1087, 2001.
3. Ceiler DL, Nelissen-Vrancken HJ, De Mey JG, and Smits JF. Effect of chronic blockade of angiotensin II-receptor subtypes on aortic compliance in rats with myocardial infarction. J Cardiovasc Pharmacol 31: 630-637, 1998.
4. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, and Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39: 269-274, 2002.
5. phox in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 279: H2234-H2240, 2000.
6. phox have distinct roles in the regulation of electron flow in NADPH oxidase. J Biol Chem 270: 6543-6548, 1995.
7. Deng X, Welch WJ, and Wilcox CS. Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension 27: 1173-1179, 1996.
8. Dobrian AD, Schriver SD, and Prewitt RL. Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension. Hypertension 38: 361-366, 2001.
9. phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
10. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, and Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105: 1631-1639, 2000.
11. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, and Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res 85: 23-28, 1999.
12. Geiszt M, Kopp JB, Várnai P, and Leto TL. Identification of renox, an NADPH oxidase in kidney. Proc Natl Acad Sci USA 97: 8010-8014, 2000.
13. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
14. Gryglewski RJ, Palmer RMJ, and Moncada S. Superoxide anion is involved in breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454-456, 1986.
15. Hornig B, Landmesser U, Kohler H, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, and Drexler H. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease. Circulation 103: 799-805, 2001.
16. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, and Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol Heart Circ Physiol 271: H1626-H1634, 1996.
17. Kawada N, Chabrashvili T, Wang D, Umans JG, Pallone T, Imai E, Welch WJ, and Wilcox CS. Renal hemodynamics and NAD(P)H oxidase in a mouse model of Ang II slow pressor response (Abstract). J Am Soc Nephrol 12: 466A, 2001.
18. 2α in isolated rat kidney glomeruli by radical-independent mechanism. Br J Pharmacol 133: 643-650, 2001.
19. 2α in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther 282: 1658-1665, 1997.
20. phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88: 888-894, 2001.
21. Laursen JB, Rajagopalan B, Galis Z, Tarpey M, Freeman BA, and Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95: 588-593, 1997.
22. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, and Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension 37: 541-546, 2001.
23. 2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension 31: 487-492, 1998.
24. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, Muller DN, Fiebeler A, Ganten U, Ganten D, and Luft FC. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 37: 414-418, 2001.
25. 2 receptor subtypes in the rat kidney. Am J Physiol Renal Physiol 277: F437-F446, 1999.
26. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, and Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-E65, 2002.
27. Negishi H, Ikeda K, Sagara M, Sawamura M, and Yamori Y. Increased oxidative DNA damage in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 26: 482-484, 1999.
28. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian RX, Kimura S, and Youichi A. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 37: 77-83, 2001.
29. phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32: 331-337, 1998.
30. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, and Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 94: 14483-14488, 1997.
31. 1 receptor antagonist candesartan in young spontaneously hypertensive rats. J Am Soc Nephrol 10, Suppl 11: S116-S119, 1999.
32. 2α by human monocytes. J Biol Chem 271: 8919-8924, 1996.
33. 2α. J Biol Chem 270: 9800-9808, 1995.
34. 2α by human platelets. Agents Actions Suppl 45: 27-31, 2002.
35. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
36. 2-isoprostanes in rats. Hypertension 35: 476-479, 2000.
37. Reilly M, Delanty N, Lawson JA, and FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94: 19-25, 1996.
38. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28: 505-513, 2000.
39. 2α. Hypertension 33: 424-428, 1999.
40. Shibata K, Makino I, Shibaguchi H, Niwa M, Katsuragi T, and Furukawa T. Up-regulation of angiotensin type 2 receptor mRNA by angiotensin II in rat cortical cells. Biochem Biophys Res Commun 239: 633-637, 1997.
41. 1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 97: 1978-1982, 1996.
42. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, and Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 131: 667-672, 2000.
43. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, and Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401: 79-82, 1999.
44. Thannickal VJ and Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279: L1005-L1028, 2000.
45. Thrasher AJ, Keep NH, Wientjes F, and Segal AW. Chronic granulomatous disease. Biochim Biophys Acta 1227: 1-24, 1994.
46. phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90: 1205-1213, 2002.
47. Touyz RM and Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672, 2000.
48. 1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 59: 1257-1263, 2001.
49. Wilcox CS. Reactive oxygen species: role in blood pressure and kidney function. Curr Hypertens Rep 4: 160-166, 2002.
50. Winer J, Jung CK, Shackel I, and Williams PM. Development and validation of the real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270: 41-49, 1999.
51. Wingler K, Wünsch S, Kreutz R, Rothermund L, Paul M, and Schmidt HHHW. Upregulation of the vascular NAD(P)H-oxidase isoforms NOX1 and NOX4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 31: 1456-1464, 2001.